ArticleVeterinary world2025
Injectable homologous platelet-rich plasma, alone or in combination with oral omega-3 supplementation, for treating keratoconjunctivitis sicca in dogs.
Article in Veterinary world, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Safety of subconjunctival allogeneic platelet-rich plasma on normal canine eyes.Frontiers in veterinary science · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aim: Keratoconjunctivitis sicca (KCS) is a chronic inflammatory condition of the canine ocular surface primarily caused by immune-mediated destruction of lacrimal tissues. Platelet-rich plasma (PRP) is known for its regenerative and anti-inflammatory properties, while omega-3 (ω-3) fatty acids possess immunomodulatory effects. This study aimed to evaluate the efficacy of injectable homologous PRP (HPRP), alone or in combination with oral ω-3 supplementation, in improving clinical and histopathological parameters in dogs with KCS. Materials and Methods: Twenty-two dogs (44 eyes) with bilateral KCS were randomized into two treatment groups: HPRP (n = 22 eyes) and HPRP plus oral ω-3 (HPRPO; n = 22 eyes). Treatments were administered monthly for up to three sessions alongside topical lubricants. Ophthalmological evaluations - including Schirmer's tear test-1 (STT-1), tear film breakup time (TBUT), fluorescein staining, cytology of the third eyelid gland, and conjunctival histopathology - were performed at baseline and at monthly intervals up to 6 months. Results: Both groups demonstrated significant improvement in ocular clinical signs and tear secretion. STT-1 values significantly increased from baseline in both groups (p < 0.05), without significant intergroup differences. However, TBUT values were significantly higher in the HPRPO group from month 3 onwards (p < 0.05). Cytological and histological analyses revealed a significant reduction in lymphocyte and neutrophil counts and an increase in goblet cell numbers in both groups, with greater improvement in the HPRPO group (p < 0.05). Earlier resolution of corneal ulcers and reduced ocular inflammation were observed in the HPRPO group. Conclusion: Injectable HPRP, particularly when combined with oral ω-3 supplementation, is an effective therapeutic modality for managing KCS in dogs. The combination therapy enhanced tear film stability, reduced ocular inflammation, and promoted epithelial repair more effectively than HPRP alone. These findings support the synergistic effect of ω-3 fatty acids with PRP in ocular surface restoration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.